# Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion

> **NCT05245500** · PHASE1 · RECRUITING · sponsor: **Bristol-Myers Squibb** · enrollment: 336 (estimated)

## Conditions studied

- Mesothelioma
- Non Small Cell Lung Cancer
- Malignant Peripheral Nerve Sheath Tumors
- Solid Tumor
- Pancreatic Adenocarcinoma
- Advanced Solid Tumor

## Interventions

- **DRUG:** MRTX1719

## Key facts

- **NCT ID:** NCT05245500
- **Lead sponsor:** Bristol-Myers Squibb
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2022-06-09
- **Primary completion:** 2027-12-10
- **Final completion:** 2027-12-10
- **Target enrollment:** 336 (ESTIMATED)
- **Last updated:** 2025-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05245500

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05245500, "Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion". Retrieved via AI Analytics 2026-07-20 from https://api.ai-analytics.org/clinical/NCT05245500. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*